Exhibit 99.1

CONTACT:

 

Jill Smith

Director, Corporate Communications

240.449.1250

jsmith@panacos.com

 

Peyton Marshall

Executive Vice President & CFO

617.926.1551

pmarshall@panacos.com

 

Panacos Reports Fourth Quarter and Full Year Results for 2005

Company Updates Progress Toward Initiating PA-457 Phase 2b Clinical Trial

Watertown, MA (February 14, 2006)

– Panacos Pharmaceuticals, Inc. (Nasdaq: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced its financial results for the quarter and year ended December 31, 2005.

Financial Highlights

For the fourth quarter of 2005, Panacos reported a net loss of $8.3 million or $0.17 per share versus a net loss of $4.5 million which resulted in a $3.49 net loss per share for the fourth quarter of 2004. Revenue from research funding in the fourth quarter of 2005 declined $0.3 million to $0.2 million, versus $0.5 million for the fourth quarter of 2004 as a result of lower NIH grant funding in 2005 and completion of work performed under other NIH grants in the second quarter of 2005.

Research and development expenses in the fourth quarter of 2005 increased to $7.0 million from $4.4 million in the fourth quarter of 2004, primarily as a result of a non-cash stock compensation charge of $2.4 million associated with the resignation of the Company’s Chief Science Officer announced in November 2005. General and administrative expenses in the fourth quarter of 2005 increased to $2.2 million from $0.6 million in the fourth quarter of 2004, primarily as a result of adding the public company infrastructure of V.I. Technologies, Inc. as a result of the merger in March 2005.

Unrestricted cash and cash equivalents were $87.1 million at December 31, 2005. As of December 31, 2005 the Company had approximately 49.9 million common shares outstanding.


The following information was filed by Panacos Pharmaceuticals, Inc. (PANC) on Tuesday, February 14, 2006 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Panacos Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Panacos Pharmaceuticals, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account